ArticleEMBO molecular medicine2013
Next generation therapeutics for Alzheimer's disease.
Article in EMBO molecular medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effects of computerised cognitive training on cognitive impairment: a meta-analysis.Journal of neurology · 2021Pooled it
- Trial
- Sustained Cognitive Improvement in Alzheimer's Disease Patients Following a Precision Medicine Protocol: Case Series.Biomedicines · 2024Article
- Current and Near-Future Treatment of Alzheimer's Disease.Current neuropharmacology · 2022Article
- The Immunopathogenesis of Alzheimer's Disease Is Related to the Composition of Gut Microbiota.Nutrients · 2021Review
- Article
- Direct Transcriptional Effects of Apolipoprotein E.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2016Article
- Dynamic self-guiding analysis of Alzheimer's disease.Oncotarget · 2015Review
- Exploring the association between interleukin-1β and its interacting proteins in Alzheimer's disease.Molecular medicine reports · 2015Article
- Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarker.Current pharmaceutical design · 2015Review
- High-Fat-Diet-Induced Weight Gain Ameliorates Bone Loss without Exacerbating AβPP Processing and Cognition in Female APP/PS1 Mice.Frontiers in cellular neuroscience · 2014Article
- Neuroprotective Sirtuin ratio reversed by ApoE4.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To date, no truly effective therapy has been developed for Alzheimer's disease or mild cognitive impairment. In searching for new approaches that may succeed where previous ones have failed, it may be instructive to consider the successful therapeutic developments for other chronic illnesses such as cancer and human immunodeficiency virus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.